The addition of tyrosine kinase inhibitors (TKIs), such as imatinib, which inhibits the activity of the BCR-ABL fusion gene, has reduced CML from a death sentence to a manageable and stable disease. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.